698 results on '"Pijnenburg, Yolande a.L."'
Search Results
2. Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury
3. Diagnostic Instability Over Time in the Late-Onset Frontal Lobe Syndrome: When Can We Say it's FTD?
4. Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood
5. Overlap of Neuroanatomical Involvement in Frontotemporal Dementia and Primary Psychiatric Disorders: A Meta-analysis
6. The Benson Complex Figure Test detects deficits in visuoconstruction and visual memory in symptomatic familial frontotemporal dementia: A GENFI study
7. Spatial distributions of white matter hyperintensities on brain MRI: A pooled analysis of individual participant data from 11 memory clinic cohorts
8. Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid
9. Everyday functioning in young onset dementia: differences in diagnostic groups independent of disease stage.
10. Comparing and linking the Mini-Mental State Examination and Montreal Cognitive Assessment in the Amsterdam Dementia Cohort.
11. Cortical and subcortical changes in resting-state neuronal activity and connectivity in early symptomatic ALS and advanced frontotemporal dementia
12. Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes
13. Frontotemporal dementia, music perception and social cognition share neurobiological circuits: A meta-analysis
14. Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer’s disease subgroups
15. Clinical presentation and differential diagnosis of dementia in younger people
16. Distinctive cell-free DNA methylation characterizes presymptomatic genetic frontotemporal dementia
17. Visual associative learning to detect early episodic memory deficits and distinguish Alzheimer's disease from other types of dementia.
18. Rationale and Design of the “DIagnostic and Prognostic Precision Algorithm for behavioral variant Frontotemporal Dementia” (DIPPA-FTD) Study: A Study Aiming to Distinguish Early Stage Sporadic FTD from Late-Onset Primary Psychiatric Disorders
19. Plasma pTau‐217 and NfL concentrations across diagnoses in an unselected memory clinic cohort
20. Amyloid‐β and tau accumulation in traumatic brain injury: A study of Vietnam war veterans
21. Differential Expression of Synaptic Biomarkers in the Cerebrospinal Fluid Differentiates Behavioural Variant of Frontotemporal Dementia from Primary Psychiatric Disorders and Alzheimer’s Disease
22. Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort
23. The proteomic profile of Von Economo neurons supports their selective vulnerability in bvFTD
24. Individualised prognostic models using plasma biomarkers for clinical progression to Alzheimer’s disease dementia in non‐demented elderly
25. CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
26. Identifying microglial CSF biomarkers specifically dysregulated in either the preclinical or the dementia stage of Alzheimer’s disease
27. Detection of early Alzheimer’s disease at the eye clinic: The BeyeOMARKER study
28. Tau‐PET signal in Alzheimer’s disease is related to immune activation and synaptic signaling measured with CSF proteomics
29. Visual rating scales of atrophy to differentiate Frontotemporal dementia from Primary psychiatric disorder: results from DIPPA study
30. Plasma protein profiling reveals novel specific biomarkers reflecting the multifactorial nature of Alzheimer´s disease continuum
31. Impact of sharing Alzheimer’s disease biomarker results with individuals without dementia: a systematic review and meta‐analysis of empirical data
32. Computerized decision support is an effective approach to select memory clinic patients for amyloid‐PET
33. The impact of COVID‐19 lockdown on mortality rate in memory clinic patients
34. Mastermind of the Alzheimer’s blood‐based biomarkers: development of cutoffs and a visualization tool for use in clinical practice
35. Premorbid musical experience influences socio‐emotional functioning in behavioural variant frontotemporal dementia
36. Data driven criteria for genetic testing result in an efficient selection of patients with genetic dementia in a clinical setting
37. Data‐driven analysis of most common neurodegenerative dementias reveals atrophy patterns associated with overlapping cognitive symptoms
38. Amygdala volume as neuroimaging marker of limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) in neurodegenerative disease: a post‐mortem MRI and pathology study
39. Replication of HLA‐DRB1*04:04 allele subtype protective effect against Alzheimer’s Disease in cognitively healthy centenarians using long‐read sequencing
40. Factors modifying the association between blood‐based biomarkers for Alzheimer’s disease and amyloid status
41. Can escapees of familial AD help identify protective factors? A case report of an extremely resilient PSEN1 carrier
42. Plasma biomarkers as a diagnostic tool for amyloid status: factors affecting the frequency of false positive and false negative results
43. Motor neuron symptoms and pathology burden in de medulla oblongata of FTLD‐TDP brain donors
44. Longitudinal AD biomarkers in monozygotic twins: genetic contribution to AD biomarker concentrations over time
45. ABOARD Cohort; a national initiative to involve citizens in AD research
46. CSF proteome profiling identifies novel biomarkers for Frontotemporal Dementia and its pathological subtypes
47. Plasma pTau181 and biomarker combinations to identify Alzheimer´s disease at any stage along the AD continuum compared with both controls and non‐AD dementia
48. Late‐onset behavioural change is enriched with C9orf72 repeat expansion regardless of family history or diagnosis
49. CSF Proteomic Signatures are Associated With Cognitive Decline in the Alzheimer’s Disease Continuum
50. TREM2 AD risk variants impact pTau and microglia and astrocyte related biomarkers in cognitively unimpaired subjects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.